IMRX Immuneering Corporation

=================== ===========
CUSIP NO. 45248L100 13G PAGE 2 OF 6
=================== ===========

================================================================================
 1 NAMES OF REPORTING PERSONS
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Boston Scientific Corporation
------- ------------------------------------------------------------------------
 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
 (a) [_]
 N/A (b) [_]
------- ------------------------------------------------------------------------
 3 SEC USE ONLY


------- ------------------------------------------------------------------------
 4 CITIZENSHIP OR PLACE OF ORGANIZATION

 The State of Delaware
------- ------------------------------------------------------------------------
 5 SOLE VOTING POWER

 1,176,471
 NUMBER OF ------- -----------------------------------------------------
 SHARES 6 SHARED VOTING POWER
BENEFICIALLY
 OWNED BY 0
 EACH ------- -----------------------------------------------------
 REPORTING 7 SOLE DISPOSITIVE POWER
 PERSON
 WITH 1,176,471
 ------- -----------------------------------------------------
 8 SHARED DISPOSITIVE POWER

 0
------- ------------------------------------------------------------------------
 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 1,176,471
------- ------------------------------------------------------------------------
 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 (SEE INSTRUCTIONS) [_]
 N/A
------- ------------------------------------------------------------------------
 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 11.7%(2)
------- ------------------------------------------------------------------------
 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 CO
================================================================================
(2) Based on the number of shares outstanding on November 5, 2007 as set forth
 in the Quarterly Report on Form 10-Q for the period ended September 30,
 2007.

=================== ===========
CUSIP NO. 45248L100 13G PAGE 3 OF 6
=================== ===========

ITEM 1(A). NAME OF ISSUER:

 ImaRx Therapeutics, Inc., a Delaware corporation (the "Company")

ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

 1635 East 18th Street
 Tucson, AZ 85719

ITEM 2(A). NAME OF PERSON FILING:

 Boston Scientific Corporation

ITEM 2(B). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 One Boston Scientific Place
 Natick, MA 01760-1537

ITEM 2(C). CITIZENSHIP:

 The State of Delaware

ITEM 2(D). TITLE OF CLASS OF SECURITIES:

 Common Stock, $0.0001 par value per share, (the "shares")

ITEM 2(E). CUSIP NUMBER:

 45248L100

=================== ===========
CUSIP NO. 45248L100 13G PAGE 4 OF 6
=================== ===========


ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13D-1(B), OR 13D-2(B),
 CHECK WHETHER THE PERSON FILING IS A:

 (a) [ ] Broker or dealer registered under section 15 of the Act (15
 U.S.C. 78o).

 (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C.
 78c).

 (c) [ ] Insurance company as defined in section 3(a)(19) of the Act
 (15 U.S.C. 78c).

 (d) [ ] Investment company registered under section 8 of the
 Investment Company Act of 1940 (15 U.S.C 80a-8).

 (e) [ ] An investment adviser in accordance with
 ss.240.13d-1(b)(1)(ii)(E);

 (f) [ ] An employee benefit plan or endowment fund in accordance
 with ss.240.13d-1(b)(1)(ii)(F);

 (g) [ ] A parent holding company or control person in accordance
 with ss. 240.13d-1(b)(1)(ii)(G);

 (h) [ ] A savings associations as defined in Section 3(b) of the
 Federal Deposit Insurance Act (12 U.S.C. 1813);

 (i) [ ] A church plan that is excluded from the definition of an
 investment company under section 3(c)(14) of the Investment
 Company Act of 1940 (15 U.S.C. 80a-3);

 (j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).


ITEM 4. OWNERSHIP:

 (a) Amount beneficially owned: 1,176,471 shares

 (b) Percent of class: 11.7%

 (c) Number of shares as to which such person has: (i) Sole Power
 to vote or to direct the vote: 1,176,471

 (ii) Shared power to vote or to direct the vote: 0 shares

 (iii) Sole power to dispose or to direct the disposition of:
 1,176,471 shares

 (iv) Shared power to dispose or to direct the disposition
 of: 0 shares

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

 If this statement is being filed to report the fact that as of the
 date hereof the reporting person has ceased to be the beneficial
 owner of more than five percent of the class of securities, check
 the following: [_]

=================== ===========
CUSIP NO. 45248L100 13G PAGE 5 OF 6
=================== ===========

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

 Not applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
 THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

 Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

 Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF A GROUP:

 Not applicable.

ITEM 10. CERTIFICATION:

 By signing below I certify that, to the best of my knowledge and
 belief the securities referred to above were not acquired and are
 not held for the purpose of or with the effect of changing or
 influencing the control of the issuer of the securities an were not
 acquired and are not held in connections with or as a participant in
 any transaction having that purpose or effect.

=================== ===========
CUSIP NO. 45248L100 13G PAGE 6 OF 6
=================== ===========


 SIGNATURE

 After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


 February 14, 2008
 ------------------------------------
 (Date)



 BOSTON SCIENTIFIC CORPORATION

 By: /s/ Lawrence J. Knopf
 --------------------------------
 Name: Lawrence J. Knopf
 Title: Senior Vice-President and
 Deputy General Counsel